PD-1 pathway inhibitors have shown great success in cancer, especially in advanced melanoma, non-small-cell lung cancer, renal cell carcinoma and metastatic bladder cancer (4). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.